Ladenburg Thalmann Financial Services’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$2K	Buy	1,110 +1,090	+5,450%	+$1.03K	﹤0.01%	5152
2019 Q3	$0	Hold	20	–	–	﹤0.01%	5667
2019 Q2	$0	Hold	20	–	–	﹤0.01%	5607
2019 Q1	$0	Hold	20	–	–	﹤0.01%	5552
2018 Q4	$0	Hold	20	–	–	﹤0.01%	5558
2018 Q3	$0	Hold	20	–	–	﹤0.01%	5578
2018 Q2	$0	Hold	20	–	–	﹤0.01%	5237
2018 Q1	$0	Hold	20	–	–	﹤0.01%	5365
2017 Q4	$0	Hold	20	–	–	﹤0.01%	5286
2017 Q3	$0	Sell	20 -100	-83%	-$334	﹤0.01%	5203
2017 Q2	$0	Hold	120	–	–	﹤0.01%	5145
2017 Q1	$1K	Hold	120	–	–	﹤0.01%	4820
2016 Q4	$0	Hold	120	–	–	﹤0.01%	5124
2016 Q3	$0	Hold	120	–	–	﹤0.01%	5067
2016 Q2	$0	Hold	120	–	–	﹤0.01%	5046
2016 Q1	$1K	Hold	120	–	–	﹤0.01%	4653
2015 Q4	$1K	Sell	120 -7	-6%	-$93	﹤0.01%	4644
2015 Q3	$2K	Hold	127	–	–	﹤0.01%	4357
2015 Q2	$2K	Sell	127 -12	-9%	-$232	﹤0.01%	4433
2015 Q1	$2K	Buy	139 +12	+9%	+$270	﹤0.01%	4368
2014 Q4	$3K	Hold	127	–	–	﹤0.01%	4004
2014 Q3	$3K	Hold	127	–	–	﹤0.01%	3638
2014 Q2	$4K	Hold	127	–	–	﹤0.01%	3505
2014 Q1	$4K	Buy	127 +92	+263%	+$3.14K	﹤0.01%	3392
2013 Q4	$1K	Hold	35	–	–	﹤0.01%	3702
2013 Q3	$1K	Hold	35	–	–	﹤0.01%	3669
2013 Q2	$0	Buy	+35	New	+$410	﹤0.01%	3783

Other funds holding CTIC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CTIC Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its CTI BioPharma Corp. (DE) Common Stock (CTIC) stake by 5,450% in Q4 2019, buying an estimated $1.03K and bringing the position to 1,110 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #5152.

Ladenburg Thalmann Financial Services first reported a position in CTIC in Q2 2013 and has held it in 27 quarters since. The position peaked at $4K in Q2 2014. 40 funds tracked by Wall St. Rank hold CTIC as of Q4 2019.

Ladenburg Thalmann Financial Services held 1,110 shares of CTI BioPharma Corp. (DE) Common Stock worth $2K as of Q4 2019.
Ladenburg Thalmann Financial Services bought 1,090 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2019, an estimated $1.03K.
CTI BioPharma Corp. (DE) Common Stock made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5152 holding.
Ladenburg Thalmann Financial Services first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and has held it in 27 quarters since.
Ladenburg Thalmann Financial Services's CTI BioPharma Corp. (DE) Common Stock position peaked at $4K in Q2 2014.
40 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.